{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:27:22Z","timestamp":1793888842961,"version":"4.8.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>ECD varies in terms of age of onset, clinical presentation, manifestations, organ involvement, disease severity, and survival. ECD is a neoplasm and should be adopted by the field of hematology-oncology following the World Health Organization reclassification.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016001784","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T20:50:18Z","timestamp":1486673418000},"page":"357-366","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":240,"title":["The clinical spectrum of Erdheim-Chester disease: an observational cohort study"],"prefix":"10.1182","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2372-0372","authenticated-orcid":false,"given":"Juvianee I.","family":"Estrada-Veras","sequence":"first","affiliation":[{"name":"Section on Human Biochemical Genetics, Medical Genetics Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-0952","authenticated-orcid":false,"given":"Louisa C.","family":"Boyd","sequence":"additional","affiliation":[{"name":"Section on Human Biochemical Genetics, Medical Genetics Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1926-4105","authenticated-orcid":false,"given":"Rahul H.","family":"Dave","sequence":"additional","affiliation":[{"name":"Viral Immunology and Intravital Imaging Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-5448","authenticated-orcid":false,"given":"Benjamin H.","family":"Durham","sequence":"additional","affiliation":[{"name":"Department of Pathology, Mortimer B. Zuckerman Research Center, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Xi","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan A.","family":"Malayeri","sequence":"additional","affiliation":[{"name":"Laboratory of Diagnostic Radiology Research, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0743-9369","authenticated-orcid":false,"given":"Marcus Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Gardner","sequence":"additional","affiliation":[{"name":"Dental Consult Service, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhonell R.","family":"Alvarado Enriquez","sequence":"additional","affiliation":[{"name":"Section on Human Biochemical Genetics, Medical Genetics Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikeith","family":"Shah","sequence":"additional","affiliation":[{"name":"Section on Human Biochemical Genetics, Medical Genetics Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-6171","authenticated-orcid":false,"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"name":"Human Oncology and Pathogenesis Program and"},{"name":"Leukemia Service, Department of Medicine, Mortimer B. Zuckerman Research Center, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette R.","family":"Gochuico","sequence":"additional","affiliation":[{"name":"Section on Human Biochemical Genetics, Medical Genetics Branch, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Raffeld","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-0301","authenticated-orcid":false,"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Gahl","sequence":"additional","affiliation":[{"name":"Section on Human Biochemical Genetics, Medical Genetics Branch, and"},{"name":"Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,2,9]]},"reference":[{"key":"2019111606373695200_B1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/BF01942684","article-title":"Uber Lipoidgranulomatose","volume":"279","author":"Chester","year":"1930","journal-title":"Virchows Arch Pathol Anat."},{"issue":"22","key":"2019111606373695200_B2","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111606373695200_B3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00005792-199605000-00005","article-title":"Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases","volume":"75","author":"Veyssier-Belot","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2019111606373695200_B4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11926-014-0412-0","article-title":"Erdheim-Chester disease","volume":"16","author":"Haroche","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"2019111606373695200_B5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejim.2015.03.004","article-title":"Erdheim-Chester disease","volume":"26","author":"Campochiaro","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"20","key":"2019111606373695200_B6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111606373695200_B7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","article-title":"Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease","volume":"124","author":"Diamond","year":"2014","journal-title":"Blood"},{"key":"2019111606373695200_B8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1750-1172-8-137","article-title":"Erdheim-Chester Disease: a comprehensive review of the literature","volume":"8","author":"Mazor","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2019111606373695200_B9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0272-2712(18)30132-X","article-title":"The histiocytoses","volume":"19","author":"Jaffe","year":"1999","journal-title":"Clin Lab Med"},{"issue":"20","key":"2019111606373695200_B10","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2010-04-279240","article-title":"Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease","volume":"116","author":"Aouba","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111606373695200_B11","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood-2005-06-2238","article-title":"Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha","volume":"106","author":"Braiteh","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2019111606373695200_B12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.semarthrit.2011.11.004","article-title":"Treatment of Erdheim-Chester disease with long-term high-dose interferon-\u03b1","volume":"41","author":"Hervier","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"2019111606373695200_B13","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.mayocp.2014.01.023","article-title":"Erdheim-Chester disease: characteristics and management","volume":"89","author":"Munoz","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2019111606373695200_B14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","article-title":"Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial","volume":"126","author":"Gianfreda","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111606373695200_B15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/thorax.58.11.1004","article-title":"Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone","volume":"58","author":"Bourke","year":"2003","journal-title":"Thorax"},{"issue":"31","key":"2019111606373695200_B16","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1200\/JCO.2010.29.9073","article-title":"Response of histiocytoses to imatinib mesylate: fire to ashes","volume":"28","author":"Janku","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111606373695200_B17","first-page":"576","article-title":"Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review [in Czech]","volume":"57","author":"Adam","year":"2011","journal-title":"Vnitr Lek"},{"issue":"5","key":"2019111606373695200_B18","first-page":"367","article-title":"Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide [in Czech]","volume":"24","author":"Adam","year":"2011","journal-title":"Klin Onkol"},{"key":"2019111606373695200_B19","first-page":"269359","article-title":"High-dose methotrexate for the treatment of relapsed central nervous system erdheim-chester disease","volume":"2014","author":"Ho","year":"2014","journal-title":"Case Rep Hematol"},{"issue":"4","key":"2019111606373695200_B20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/pbc.22636","article-title":"Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease","volume":"55","author":"Jeon","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"2019111606373695200_B21","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111606373695200_B22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","article-title":"Diverse and targetable kinase alterations drive histiocytic neoplasms","volume":"6","author":"Diamond","year":"2016","journal-title":"Cancer Discov"},{"issue":"19","key":"2019111606373695200_B23","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2014-04-570937","article-title":"Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease","volume":"124","author":"Emile","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111606373695200_B24","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111606373695200_B25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2012-07-446286","article-title":"Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation","volume":"121","author":"Haroche","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2019111606373695200_B26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","article-title":"Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease","volume":"33","author":"Haroche","year":"2015","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111606373695200_B27","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1212\/WNL.0b013e3181c67bbc","article-title":"Characteristic brain MRI appearance of Erdheim-Chester disease","volume":"73","author":"Bianco","year":"2009","journal-title":"Neurology"},{"issue":"1","key":"2019111606373695200_B28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2169\/internalmedicine.48.1448","article-title":"Cardiac Erdheim-Chester","volume":"48","author":"Bassou","year":"2009","journal-title":"Intern Med"},{"issue":"2","key":"2019111606373695200_B29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1148\/radiol.10090320","article-title":"Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings","volume":"255","author":"Drier","year":"2010","journal-title":"Radiology"},{"issue":"10","key":"2019111606373695200_B30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00415-006-0160-9","article-title":"Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature","volume":"253","author":"Lachenal","year":"2006","journal-title":"J Neurol"},{"issue":"2","key":"2019111606373695200_B31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.annder.2012.06.036","article-title":"Cutaneous revelation of Rosai-Dorfman disease: 7 cases [in French]","volume":"140","author":"Vuong","year":"2013","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"2019111606373695200_B32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3171\/2014.10.PEDS14378","article-title":"Spontaneous regression of infantile dural-based non-Langerhans cell histiocytosis after surgery: case report","volume":"15","author":"Miyake","year":"2015","journal-title":"J Neurosurg Pediatr"},{"issue":"8","key":"2019111606373695200_B33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1346-8138.2001.tb00002.x","article-title":"Clinicohistopathologic comparison of adult type and juvenile type xanthogranulomas in Korea","volume":"28","author":"Chang","year":"2001","journal-title":"J Dermatol"},{"issue":"25","key":"2019111606373695200_B34","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1161\/CIRCULATIONAHA.108.825075","article-title":"Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients","volume":"119","author":"Haroche","year":"2009","journal-title":"Circulation"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/6\/357\/878134\/advances001784.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/6\/357\/878134\/advances001784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T06:37:54Z","timestamp":1573886274000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/6\/357\/15610\/The-clinical-spectrum-of-ErdheimChester-disease-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,9]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016001784","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,9]]}}}